首页> The New England journal of medicine> Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Eric L,Simpson

第一单位： From the Department of Dermatology, Oregon Health and Science University (E.L.S.), and Oregon Medical Research Center (A.B.) - both in Portland; the Department of Dermatology and Allergy, University of Bonn, Bonn (T.B.), the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin (M.W.), and the Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich (A.W.) - all in Germany; the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.), the Department of Dermatology, University of Rochester Medical Center, Rochester (L.A.B.), and Regeneron Pharmaceuticals, Tarrytown (Y.S., N.M.H.G., B.A., V.M., A.G., N.S., G.D.Y., M.A.) - all in New York; the Dermatology Research Unit, University of Sheffield Medical School, Sheffield, United Kingdom (M.J.C.); the Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago (J.I.S.); the Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark (M.D.); the Department of Dermatology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Osaka, Japan (Y.K.); the Department of Dermatology, University Hospital of Nice, Nice (J.-P.L.), and Sanofi, Chilly-Mazarin (L.E.) - both in France; the Clinic of Dermatology, Tartu University Hospital, Tartu, Estonia (K.K.); the Department of Medicine, Université Laval, Hôpital Hôtel-Dieu de Québec, Quebec, QC, Canada (Y.P.); and Sanofi, Bridgewater, NJ (G.P., H.S.).

作者： Eric L,Simpson ^[1] ; Thomas,Bieber ^[1] ; Emma,Guttman-Yassky ^[1] ; Lisa A,Beck ^[1] ; Andrew,Blauvelt ^[1] ; Michael J,Cork ^[1] ; Jonathan I,Silverberg ^[1] ; Mette,Deleuran ^[1] ; Yoko,Kataoka ^[1] ; Jean-Philippe,Lacour ^[1] ; Külli,Kingo ^[1] ; Margitta,Worm ^[1] ; Yves,Poulin ^[1] ; Andreas,Wollenberg ^[1] ; Yuhwen,Soo ^[1] ; Neil M H,Graham ^[1] ; Gianluca,Pirozzi ^[1] ; Bolanle,Akinlade ^[1] ; Heribert,Staudinger ^[1] ; Vera,Mastey ^[1] ; Laurent,Eckert ^[1] ; Abhijit,Gadkari ^[1] ; Neil,Stahl ^[1] ; George D,Yancopoulos ^[1] ; Marius,Ardeleanu ^[1] ; SOLO 1 and SOLO 2 Investigators

作者单位： From the Department of Dermatology, Oregon Health and Science University (E.L.S.), and Oregon Medical Research Center (A.B.) - both in Portland; the Department of Dermatology and Allergy, University of Bonn, Bonn (T.B.), the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin (M.W.), and the Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich (A.W.) - all in Germany; the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.), the Department of Dermatology, University of Rochester Medical Center, Rochester (L.A.B.), and Regeneron Pharmaceuticals, Tarrytown (Y.S., N.M.H.G., B.A., V.M., A.G., N.S., G.D.Y., M.A.) - all in New York; the Dermatology Research Unit, University of Sheffield Medical School, Sheffield, United Kingdom (M.J.C.); the Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago (J.I.S.); the Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark (M.D.); the Department of Dermatology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Osaka, Japan (Y.K.); the Department of Dermatology, University Hospital of Nice, Nice (J.-P.L.), and Sanofi, Chilly-Mazarin (L.E.) - both in France; the Clinic of Dermatology, Tartu University Hospital, Tartu, Estonia (K.K.); the Department of Medicine, Université Laval, Hôpital Hôtel-Dieu de Québec, Quebec, QC, Canada (Y.P.); and Sanofi, Bridgewater, NJ (G.P., H.S.). ^[1]